Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 5/20 | 0.43 |
| ▸ | PREP | P48147 | 2/20 | 0.43 |
| ▸ | NEK2 | P51955 | 4/20 | 0.42 |
| ▸ | ATR | Q13535 | 6/20 | 0.41 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.40 |
| ▸ | PRKDC | P78527 | 1/20 | 0.37 |
| ▸ | ATM | Q13315 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12198450 | 0.95 | ATR (0.43) | KCNH2PREPNEK2ATRCHEK1 | |
| SCHEMBL2502121 | 0.95 | ATR (0.49) | NEK2ATRPRKDCATM | |
| SCHEMBL2500375 | 0.92 | ADK (0.44) | KCNH2PREPNEK2ATR | |
| SCHEMBL2507103 | 0.89 | PRKDC (0.42) | KCNH2NEK2ATRPRKDCATM | |
| SCHEMBL2504524 | 0.89 | RAB9A (0.43) | KCNH2PREPNEK2ATR | |
| SCHEMBL2506344 | 0.88 | ATR (0.47) | KCNH2PREPNEK2ATRCHEK1 | |
| SCHEMBL15457713 | 0.87 | ATR (0.38) | KCNH2PREPNEK2ATRCHEK1 | |
| SCHEMBL29903476 | 0.86 | PREP (0.43) | PREPNEK2ATRPRKDC | |
| SCHEMBL2506338 | 0.86 | PREP (0.43) | PREPNEK2ATRPRKDC | |
| SCHEMBL2506364 | 0.85 | ATR (0.42) | KCNH2PREPATRPRKDCATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9075058-B2 | Coelenterazine analogues and coelenteramide analogues | JNC CORPORATION (JP) | 2015-07-07 | — | — | US | disclosed |
| US-9056840-B2 | Coelenterazine analogues and coelenteramide analogues | JNC CORPORATION (JP) | 2015-06-16 | — | — | US | disclosed |
| US-20150153344-A1 | COELENTERAZINE ANALOGUES AND COELENTERAMIDE ANALOGUES | JNC CORP (JP) | 2015-06-04 | — | — | US | disclosed |
| US-8883432-B2 | Coelenterazine analogues and coelenteramide analogues | JNC CORPORATION (JP) | 2014-11-11 | — | — | US | disclosed |
| US-20140316137-A1 | COELENTERAZINE ANALOGUES AND COELENTERAMIDE ANALOGUES | JNC CORP (JP) | 2014-10-23 | — | — | US | disclosed |
| US-20140120538-A1 | COELENTERAZINE ANALOGUES AND COELENTERAMIDE ANALOGUES | NATIONAL UNIVERSITY CORPORATION TOKYO MEDICAL AND DENTAL UNIVERSITY (JP) | 2014-05-01 | — | — | US | disclosed |
| US-8642281-B2 | Coelenterazine analogues and coelenteramide analogues | JNC CORPORATION (JP) | 2014-02-04 | — | — | US | disclosed |
| US-20110244481-A1 | COELENTERAZINE ANALOGUES AND COELENTERAMIDE ANALOGUES | JNC CORPORATION (JP) | 2011-10-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140120538-A1 | COELENTERAZINE ANALOGUES AND COELENTERAMIDE ANALOGUES | CCKAR, SI, GLP1R | KCNH2 217/4885PREP 372/4885NEK2 3769/4885 |
| US-20140316137-A1 | COELENTERAZINE ANALOGUES AND COELENTERAMIDE ANALOGUES | CCKAR, SI, GLP1R | KCNH2 251/4885PREP 437/4885NEK2 3665/4885 |
| US-20110244481-A1 | COELENTERAZINE ANALOGUES AND COELENTERAMIDE ANALOGUES | CCKAR, SI, GLP1R | KCNH2 217/4885PREP 372/4885NEK2 3769/4885 |
| US-20150153344-A1 | COELENTERAZINE ANALOGUES AND COELENTERAMIDE ANALOGUES | CCKAR, SI, GLP1R | KCNH2 217/4885PREP 372/4885NEK2 3769/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.